Pliant Therapeutics Inc. (PLRX)
NASDAQ: PLRX
· Real-Time Price · USD
1.34
-0.04 (-2.90%)
At close: Jun 16, 2025, 3:59 PM
1.41
4.83%
After-hours: Jun 16, 2025, 07:08 PM EDT
-2.90% (1D)
| Bid | 1.33 |
| Market Cap | 82.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -219.51M |
| EPS (ttm) | -3.42 |
| PE Ratio (ttm) | -0.39 |
| Forward PE | -0.78 |
| Analyst | Hold |
| Ask | 1.65 |
| Volume | 567,889 |
| Avg. Volume (20D) | 1,178,034 |
| Open | 1.38 |
| Previous Close | 1.38 |
| Day's Range | 1.33 - 1.41 |
| 52-Week Range | 1.10 - 16.10 |
| Beta | 1.36 |
About PLRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PLRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PLRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-59.88%
Pilant Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
4 months ago
+20.96%
Pliant Therapeutics shares are trading higher after the company announced it initiated the assembly of an outside expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
2 months ago · accessnewswire.com
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsNEW YORK CITY, NY / ACCESS Newswire / April 5, 2025 / Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics...
